AK

Achim H. Krauss

AB AbbVie: 19 patents #99 of 1,308Top 8%
NS Nicox S.A.: 2 patents #36 of 91Top 40%
📍 San Marcos, CA: #62 of 897 inventorsTop 7%
🗺 California: #21,822 of 386,348 inventorsTop 6%
Overall (All Time): #159,359 of 4,157,543Top 4%
25
Patents All Time

Issued Patents All Time

Showing 1–25 of 25 patents

Patent #TitleCo-InventorsDate
12350277 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Charles BOSWORTH 2025-07-08
11759472 Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface Charles BOSWORTH 2023-09-19
10751334 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions 2020-08-25
10413535 Pharmaceutical compositions comprising an integrin ALPHA4 antagonist for use in treating ocular inflammatory conditions 2019-09-17
8101658 Nitric oxide donating prostamides Francesca Benedini, Stefano Biondi, Valerio Chiroli, Wesley Kwan Mung Chong, Liming Dong +4 more 2012-01-24
7718656 Prostaglandin derivatives Francesca Benedini, Valerio Chiroli, Wesley Kwan Mung Chong, Michael NIESMAN, Ennio Ongini 2010-05-18
7612082 Prostaglandin EP4 antagonists Larry A. Wheeler, Michael E. Garst, Yanbin Liang, David F. Woodward, Robert M. Burk +4 more 2009-11-03
7273883 Prostaglandin EP4 antagonist David F. Woodward, Yariv Donde, Robert M. Burk 2007-09-25
7217725 Prostaglandin D2 antagonist David F. Woodward, Yariv Donde, Robert M. Burk 2007-05-15
7070768 Method for imparting artificial tan to human skin 2006-07-04
7045634 Prostamide receptor antagonists David F. Woodward 2006-05-16
7019149 Thromboxane ligands without blood clotting side effects Robert M. Burk, David F. Woodward 2006-03-28
6956057 EP4 agonists as agents for lowering intraocular pressure David F. Woodward, Robert M. Burk, Mark Holoboski, Mari Posner 2005-10-18
6818779 Thromboxane ligands without blood clotting side effects Robert M. Burk, David F. Woodward 2004-11-16
6713268 Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation David F. Woodward, Licheng Shi, Clayton S. Spada, Sheila Mac Neil, Linda C. Smith-Thomas 2004-03-30
6462077 Thromboxane ligands without blood clotting side effects Robert M. Burk, David F. Woodward 2002-10-08
6395787 Ocular hypotensive lipids David F. Woodward, Helen Usansky, Steven W. Andrews, Robert M. Burk, June Chen +1 more 2002-05-28
6090845 Thromboxane ligands Robert M. Burk, David F. Woodward 2000-07-18
6017953 Thromboxane ligands Robert M. Burk, David F. Woodward 2000-01-25
5741812 Thromboxane ligands without blood clotting side effects Robert M. Burk, David F. Woodward 1998-04-21
5652236 Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors 1997-07-29
5650431 Thromboxane ligands without blood clotting side effects Robert M. Burk, David F. Woodward 1997-07-22
5602143 Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors 1997-02-11
5516791 7-[carboxyakyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1]octane and derivatives thereof Robert M. Burk, David F. Woodward 1996-05-14
5416106 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof Robert M. Burk, David F. Woodward 1995-05-16